Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. Sekulic, A., Hainsworth, J. D., Lewis, K. D., Oro, A. E., Gesierich, A., Mortier, L., Dirix, L., Bernard, S., Dreno, B., Murrell, D. F., Williams, S., Hou, J., Fisher, D., Hauschild, A. AMER SOC CLINICAL ONCOLOGY. 2014

View details for DOI 10.1200/jco.2014.32.15_suppl.9081

View details for Web of Science ID 000358613204366